Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006, 150(2):191-204 | DOI: 10.5507/bp.2006.028

Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases

Zdenka Navratilova
Department of Immunology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

Background: Chemokines and chemokine receptors are major mediators of leukocyte trafficking into the sites of the immune response. They participate in defence against microbial infection, in Th1/Th2 polarization of the immune response, allograft rejection and angiogenesis/angiostasis as well as in tumorigenesis and metastasis. To date, several functional polymorphisms of chemokine and chemokine receptor genes have been discovered that are able to deregulate chemokine system and, therefore, they may interfere with the pathogenesis of a large number of inflammatory and other diseases. In this review we focus on the known polymorphisms of two chemokines: CCL2, CCL5 and their corresponding receptors (CCR2, CCR5) and we also discuss their associations with susceptibility and progression to selected immune-mediated diseases.

Methods And Results: Based on relevant literature this article gives a short overview of case-control and family studies regarding effect of the genetic factors on diseases such as coronary artery disease, systemic lupus erythematosus, diabetes mellitus, lung diseases and others.

Conclusion: Recent advance in the identification of chemokine genetic background of the diseases could provide opportunity for pharmacological treatment. However, we need more information about posttranscriptional events to understand functional relevance of polymorphisms and to discovery new avenues to blocking disease de velopment.

Keywords: Chemokines, CCL2, CCR2, CCL5, CCR5, Gene polymorphisms

Received: October 19, 2006; Accepted: November 21, 2006; Published: December 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Navratilova, Z. (2006). Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomedical papers, 150(2), 191-204. doi: 10.5507/bp.2006.028
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol. 2001; 78:57-110. Go to original source... Go to PubMed...
    2. Mackay CR. Chemokines: what chemokine is that? Curr Biol. 1997; 7:384-6. Go to original source... Go to PubMed...
    3. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004; 95:858-66. Go to original source... Go to PubMed...
    4. McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keaney JF Jr et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation. 2005; 112: 1113-20. Go to original source... Go to PubMed...
    5. Liu H, Shioda T, Nagai Y, Iwamoto A, Wasi C, Ma J et al. Distribution of HIV-1 disease modifying regulated on activation normal T cell expressed and secreted haplotypes in Asian, African and Caucasian individuals. French ALT and IMMUNOCO Study Group. AIDS. 1999; 13:2602-3. Go to original source... Go to PubMed...
    6. An P, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A. 2002; 99:10002-7. Go to original source... Go to PubMed...
    7. Hladik F, Liu H, Speelmon E, Livingston-Rosanoff D, Wilson S, Sakchalathorn P et al. (2005) Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol. 2005; 79:11677-84. Go to original source... Go to PubMed...
    8. Arndt PG, Suzuki N, Avdi NJ, Malcolm KC, Worthen GS. Lipopolysaccharide-induced c-Jun NH2-terminal kinase activation in human neutrophils: role of phosphatidylinositol 3-Kinase and Syk-mediated pathways. J Biol Chem. 2004; 279:10883-91. Go to original source... Go to PubMed...
    9. Lee YW, Eum SY, Chen KC, Hennig B, Toborek M. Gene expression profile in interleukin-4-stimulated human vascular endothelial cells. Mol Med. 2004; 10:19-27. Go to original source... Go to PubMed...
    10. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum. 2001; 44:2665-78. Go to original source... Go to PubMed...
    11. Mestdagt M, Polette M, Buttice G, Noel A, Ueda A, Foidart JM et al. Transactivation of MCP-1/CCL2 by beta-catenin/TCF-4 in human breast cancer cells. Int J Cancer. 2006; 118:35-42. Go to original source... Go to PubMed...
    12. Jost MM, Ninci E, Meder B, Kempf C, Van Royen N, Hua J et al. Divergent effects of GM-CSF and TGFbeta1 on bone marrowderived macrophage arginase-1 activity, MCP-1 expression, and matrix metalloproteinase-12: a potential role during arteriogenesis. FASEB J. 2003; 17:2281-3. Go to original source... Go to PubMed...
    13. Mehrabian M, Sparkes RS, Mohandas T, Fogelman AM, Lusis AJ. Localization of monocyte chemotactic protein-1 gene (SCYA2) to human chromosome 17q11.2-q21.1. Genomics. 1991; 9:200-3. Go to original source... Go to PubMed...
    14. Rollins BJ, Morton CC, Ledbetter DH, Eddy R.L, Shows TB. Assignment of the human small inducible cytokine A2 gene, SCYA2 (encoding JE or MCP-1), to 17q11.2-12: evolutionary relatedness of cytokines clustered at the same locus. Genomics 1991; 10:489-92. Go to original source... Go to PubMed...
    15. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis. 2001; 158:233-9. Go to original source... Go to PubMed...
    16. Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J. 2004; 25:1438-46. Go to original source... Go to PubMed...
    17. Flex A, Gaetani E, Papalo P, Straface G, Proia AS, Pecorini G et al. Proinflammatory Genetic Profiles in Subjects With History of Ischemic Stroke. Stroke. 2004; 35:2270. Go to original source... Go to PubMed...
    18. Bjarnadottir K, Eiriksdottir G, Aspelund T, Gudnason V. Examination of genetic effects of polymorphisms in the MCP-1 and CCR2 genes on MI in the Icelandic population. Atherosclerosis. 2005 Go to original source...
    19. A genome-wide search for asthma susceptibility loci in ethnically diverse populations. The Collaborative Study on the Genetics of Asthma (CSGA). Nat Genet. 1997; 15:389-92. Go to PubMed...
    20. Szalai C, Kozma GT, Nagy A, Bojszko A, Krikovszky D, Szabo T et al. A. Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol. 2001; 108:375-81. Go to original source... Go to PubMed...
    21. Kozma GT, Falus A, Bojszko A, Krikovszky D, Szabo T, Nagy A et al. Lack of association between atopic eczema/dermatitis syndrome and polymorphisms in the promoter region of RANTES and regulatory region of MCP-1. Allergy. 2002; 57:160-3. Go to original source... Go to PubMed...
    22. Takada T, Suzuki E, Morohashi K, Omori K, Gejyo F. MCP-1 and MIP-1A gene polymorphisms in Japanese patients with sarcoidosis. Intern Med. 2002; 41:813-8. Go to original source... Go to PubMed...
    23. Kroner A, Maurer M, Loserth S, Kleinschnitz C, Hemmer B, Rosche B et al. Analysis of the monocyte chemoattractant protein 1 -2518 promoter polymorphism in patients with multiple sclerosis. Tissue Antigens. 2004; 64:70-3. Go to original source... Go to PubMed...
    24. Karrer S, Bosserhoff AK, Weiderer P, Distler O, Landthaler M, Szeimies RM et al. The -2518 promotor polymorphism in the MCP- 1 gene is associated with systemic sclerosis. J Invest Dermatol. 2005; 124:92-8. Go to original source... Go to PubMed...
    25. Gonzalez-Escribano MF, Torres B, Aguilar F, Rodriguez R, Garcia A, Valenzuela A et al. MCP-1 promoter polymorphism in Spanish patients with rheumatoid arthritis. Hum Immunol. 2003; 64:741- 4. Go to original source... Go to PubMed...
    26. Lee YH, Kim HJ, Rho YH, Choi SJ, Ji JD, Song GG. Functional polymorphisms in matrix metalloproteinase-1 and monocyte chemoattractant protein-1 and rheumatoid arthritis. Scand J Rheumatol. 2003; 32:235-9. Go to original source...
    27. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S et al. (2002) HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A. 2002; 99: 13795-800. Go to original source... Go to PubMed...
    28. Letendre S, Marquie-Beck J, Singh KK, de Almeida S, Zimmerman J, Spector SA et al. The monocyte chemotactic protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. J Neuroimmunol. 2004; 157:193-6. Go to original source... Go to PubMed...
    29. Frade JM, Llorente M, Mellado M, Alcami J, Gutierrez-Ramos JC, Zaballos A et al. The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection. J Clin Invest. 1997; 100:497-502. Go to original source... Go to PubMed...
    30. Cinque P, Vago L, Mengozzi M, Torri V, Ceresa D, Vicenzi E et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS. 1998; 12:1327-32. Go to original source... Go to PubMed...
    31. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci. 2006; 26:1098-106. Go to original source... Go to PubMed...
    32. Singh KK, Ellis RJ, Marquie-Beck J, Letendre S, Heaton RK, Grant I et al. CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. J Neuroimmunol. 2004; 157: 185-92. Go to original source... Go to PubMed...
    33. Modi WS, Goedert JJ, Strathdee S, Buchbinder S, Detels R, Donfield S et al. MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. AIDS. 2003; 17:2357-65. Go to original source... Go to PubMed...
    34. Kim HL, Lee DS, Yang SH, Lim CS, Chung JH, Kim S et al. The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Am J Kidney Dis. 2002; 40:1146-52. Go to original source... Go to PubMed...
    35. Tucci M, Barnes EV, Sobel ES, Croker BP, Segal MS, Reeves WH et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum. 2004; 50:1842-9. Go to original source... Go to PubMed...
    36. Simeoni E, Hoffmann MM, Winkelmann BR, Ruiz J, Fleury S, Boehm BO et al. Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia. 2004; 47:1574- 80. Go to original source... Go to PubMed...
    37. Ghilardi G, Biondi ML, La Torre A, Battaglioli L, Scorza R. Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele. Clin Chem. 2005; 51:452-5. Go to original source... Go to PubMed...
    38. Kruger B, Schroppel B, Ashkan R, Marder B, Zulke C, Murphy B et al. A Monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol. 2002; 13:2585-9. Go to original source... Go to PubMed...
    39. Schroppel B, Fischereder M, Lin M, Marder B, Schiano T, Kramer BK et al. Analysis of gene polymorphisms in the regulatory region of MCP-1, RANTES, and CCR5 in liver transplant recipients. J Clin Immunol. 2002; 22:381-5. Go to original source... Go to PubMed...
    40. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology. 2003; 125:1085-93. Go to original source... Go to PubMed...
    41. Glas J, Torok HP, Tonenchi L, Schiemann U, Folwaczny C. The -2518 promotor polymorphism in the MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection. Gastroenterology. 2004; 126:1930-1. Go to original source... Go to PubMed...
    42. Pola R, Flex A, Gaetani E, Proia AS, Papaleo P, Giorgio AD et al. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimers disease in Italians. Exp Gerontol. 2004; 39:1249-52. Go to original source... Go to PubMed...
    43. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000; 52:145-76. Go to PubMed...
    44. Valentonyte R, Hampe J, Croucher PJ, Muller-Quernheim J, Schwinger E, Schreiber S et al. Study of C-C chemokine receptor 2 alleles in sarcoidosis, with emphasis on family-based analysis. Am J Respir Crit Care Med. 2005; 171:1136-41. Go to original source... Go to PubMed...
    45. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 1997; 277:959-65. Go to original source... Go to PubMed...
    46. Anzala AO, Ball TB, Rostron T, OBrien SJ, Plummer FA, Rowland- Jones SL. CCR2-64I allele and genotype association with delayed AIDS progression in African women. University of Nairobi Collaboration for HIV Research. Lancet. 1998; 351:1632-3. Go to original source... Go to PubMed...
    47. Struyf F, Thoelen I, Charlier N, Keyaerts E, Van der Donck I et al. Prevalence of CCR5 and CCR2 HIV-coreceptor gene polymorphisms in Belgium. Hum Hered. 2000; 50:304-7. Go to original source... Go to PubMed...
    48. Lewandowska M, Franciszkiewicz K, Prokop J, Ofori H, Jagodzinski PP. Distribution of two HIV-1-resistant polymorphisms (SDF1-3A and CCR2-64I alleles) in the Polish population. J Hum Genet. 2002; 47:585-9. Go to original source... Go to PubMed...
    49. Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. A CCR2- V64I polymorphism affects stability of CCR2A isoform. AIDS. 2004; 18:729-38. Go to original source... Go to PubMed...
    50. Lee B, Doranz BJ, Rana S, Yi Y, Mellado M, Frade JM et al. Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol. 1998; 72, 7450-8. Go to original source... Go to PubMed...
    51. Mariani R, Wong S, Mulder LC, Wilkinson DA, Reinhart AL, LaRosa G et al. CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J Virol. 1999; 73: 2450-9. Go to original source... Go to PubMed...
    52. Sabbe R, Picchio GR, Pastore C, Chaloin O, Hartley O, Offord R et al. Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J Virol. 2001; 75:661-71. Go to original source... Go to PubMed...
    53. Ortlepp JR, Krantz C, Kimmel M, von Korff A, Vesper K, Schmitz F et al. Additive effects of the chemokine receptor 2, vitamin D receptor, interleukin-6 polymorphisms and cardiovascular risk factors on the prevalence of myocardial infarction in patients below 65 years. Int J Cardiol. 2005; 105:90-5. Go to original source... Go to PubMed...
    54. Petrkova J, Cermakova Z, Drabek J, Lukl J, Petrek M. CC chemokine receptor (CCR)2 polymorphism in Czech patients with myocardial infarction. Immunol Lett. 2003; 88:53-5. Go to original source... Go to PubMed...
    55. Gonzalez P, Alvarez R, Batalla A, Reguero JR, Alvarez V, Astudillo A et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. 2001; 2:191-5. Go to original source... Go to PubMed...
    56. Valdes AM, Wolfe ML, OBrien EJ, Spurr NK, Gefter W, Rut A et al. Val64Ile polymorphism in the C-C chemokine receptor 2 is associated with reduced coronary artery calcification. Arterioscler Thromb Vasc Biol. 2002; 22:1924-8. Go to original source... Go to PubMed...
    57. Hizawa N, Yamaguchi E, Furuya K, Jinushi E, Ito A, Kawakami Y. The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med. 1999; 159:2021-3. Go to original source... Go to PubMed...
    58. Petrek M, Drabek J, Kolek V, Zlamal J, Welsh KI, Bunce M et al. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 2000; 162:1000-3. Go to original source... Go to PubMed...
    59. Spagnolo P, Renzoni EA, Wells AU, Sato H, Grutters JC, Sestini P et al. C-C chemokine receptor 2 and sarcoidosis: association with Lofgrens syndrome. Am J Respir Crit Care Med. 2003; 168: 1162- 6. Go to original source... Go to PubMed...
    60. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci. 2006; 27:48-55. Go to original source... Go to PubMed...
    61. Miyagishi R, Niino M, Fukazawa T, Yabe I, Kikuchi S, Tashiro K. (2003) C-C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol. 145:135-8. Go to original source... Go to PubMed...
    62. Barcellos LF, Schito AM, Rimmler JB, Vittinghoff E, Shih A, Lincoln R et al. (2000) CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics. 51:281-8. Go to original source... Go to PubMed...
    63. van Rij RP, de Roda Husman AM, Brouwer M, Goudsmit J, Coutinho RA, Schuitemaker H. (1998) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J Infect Dis. 178:1806-11. Go to original source... Go to PubMed...
    64. Liu H, Hwangbo Y, Holte S, Lee J, Wang C, Kaupp N et al. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cellderived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J Infect Dis. 2004; 190:1055-8. Go to original source... Go to PubMed...
    65. Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP et al. International Meta-Analysis of HIV Host Genetics. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med. 2001; 135:782-95. Go to original source... Go to PubMed...
    66. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med. 1998; 4:786-93 Go to original source... Go to PubMed...
    67. Shrestha S, Strathdee SA, Galai N, Oleksyk T, Fallin MD, Mehta S et al. Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. J Infect Dis. 2006; 193:16-26. Go to original source... Go to PubMed...
    68. Schroppel B, Fischereder M, Ashkar R, Lin M, Kramer BK, Mardera B et al. The impact of polymorphisms in chemokine and chemokine receptors on outcomes in liver transplantation. Am J Transplant. 2002; 2:640-5. Go to original source... Go to PubMed...
    69. Simeoni E, Vassalli G, Seydoux C, Ramsay D, Noll G, von Segesser LK et al. CCR5, RANTES and CX3CR1 polymorphisms: possible genetic links with acute heart rejection. Transplantation. 2005; 80:1309-15. Go to original source... Go to PubMed...
    70. Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL et al. rejection in human renal transplantation. J Am Soc Nephrol. 2002; 13:754-8. Go to original source... Go to PubMed...
    71. Goulding C, McManus R, Murphy A, MacDonald G, Barrett S, Crowe J et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut. 2005; 54:1157-61. Go to original source... Go to PubMed...
    72. Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology. 2003; 38:1468-76. Go to original source... Go to PubMed...
    73. Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet. 2004; 41:59. Go to original source... Go to PubMed...
    74. Hampe J, Lynch NJ, Daniels S, Bridger S, Macpherson AJ, Stokkers P et al. Fine mapping of the chromosome 3p susceptibility locus in inflammatory bowel disease. Gut. 2001; 48:191-7. Go to original source... Go to PubMed...
    75. Rector A, Vermeire S, Thoelen I, Keyaerts E, Struyf F, Vlietinck R et al. Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. Hum Genet. 2001; 108:190-3. Go to original source... Go to PubMed...
    76. Duggal P, Winkler CA, An P, Yu XF, Farzadegan H, OBrien SJ et al. The effect of RANTES chemokine genetic variants on early HIV-1 plasma RNA among African American injection drug users. J Acquir Immune Defic Syndr. 2005; 38:584-9. Go to original source... Go to PubMed...
    77. Boger CA, Fischereder M, Deinzer M, Aslanidis C, Schmitz G, Stubanus M et al. RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis. 2005; 183:121-9. Go to original source... Go to PubMed...
    78. Gade-Andavolu R, Comings DE, MacMurray J, Vuthoori RK, Tourtellotte WW, Nagra RM et al. RANTES: a genetic risk marker for multiple sclerosis. Mult Scler. 2004; 10:536-9. Go to original source... Go to PubMed...
    79. Koppelman GH, Stine OC, Xu J, Howard TD, Zheng SL, Kauffman HF et al. Genome-wide search for atopy susceptibility genes in Dutch families with asthma. J Allergy Clin Immunol. 2002; 109:498-506. Go to original source... Go to PubMed...
    80. Fryer AA, Spiteri MA, Bianco A, Hepple M, Jones PW, Strange RC et al. The -403 G-->A promoter polymorphism in the RANTES gene is associated with atopy and asthma. Genes Immun. 2000; 1:509-14. Go to original source... Go to PubMed...
    81. Al-Abdulhadi SA, Helms PJ, Main M, Smith O, Christie G. Preferential transmission and association of the -403 G --> A promoter RANTES polymorphism with atopic asthma. Genes Immun. 2005; 6:24-30. Go to original source... Go to PubMed...
    82. Yao TC, Kuo ML, See LC, Chen LC, Yan DC, Ou LS et al. The RANTES promoter polymorphism: a genetic risk factor for nearfatal asthma in Chinese children. J Allergy Clin Immunol. 2003; 111:1285-92. Go to original source... Go to PubMed...
    83. Hizawa N, Yamaguchi E, Konno S, Tanino Y, Jinushi E, Nishimura M. A functional polymorphism in the RANTES gene promoter is associated with the development of late-onset asthma. Am J Respir Crit Care Med. 2002; 166:686-90. Go to original source... Go to PubMed...
    84. Moissidis I, Chinoy B, Yanamandra K, Napper D, Thurmon T, Bocchini J Jr et al. Association of IL-13, RANTES, and leukotriene C4 synthase gene promoter polymorphisms with asthma and/or atopy in African Americans. Genet Med. 2005; 7:406-10. Go to original source... Go to PubMed...
    85. Petrek M, Kolek V, Szotkowska J, du Bois RM. CC and C chemokine expression in pulmonary sarcoidosis. Eur Respir J. 2002; 20:1206-12. Go to original source... Go to PubMed...
    86. Takada T, Suzuki E, Ishida T, Moriyama H, Ooi H, Hasegawa T et al. Polymorphism in RANTES chemokine promoter affects extent of sarcoidosis in a Japanese population. Tissue Antigens. 2001; 58:293-8. Go to original source... Go to PubMed...
    87. Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci U S A. 2001; 98:5199-204. Go to original source... Go to PubMed...
    88. Zhao XY, Lee SS, Wong KH, Chan KC, Ma S, Yam WC et al. Effects of single nucleotide polymorphisms in the RANTES promoter region in healthy and HIV-infected indigenous Chinese. Eur J Immunogenet. 2004; 31:179-83. Go to original source... Go to PubMed...
    89. McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WE, Zimmerman PA et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS. 2000; 14:2671-8. Go to original source... Go to PubMed...
    90. Wang C, Song W, Lobashevsky E, Wilson CM, Douglas SD, Mytilineos J et al. Cytokine and chemokine gene polymorphisms among ethnically diverse North Americans with HIV-1 infection. J Acquir Immune Defic Syndr. 2004; 35:446-54. Go to original source... Go to PubMed...
    91. Vidal F, Peraire J, Domingo P, Broch M, Cairo M, Pedrol E et al. Chemokines and Long-Term Nonprogressive HIV01 Infection Study Group. Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years. J Acquir Immune Defic Syndr. 2006; 41:17-22. Go to original source... Go to PubMed...
    92. Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Ikeda F, Kanno R et al. RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. Diabetes Care. 2003; 26:892-8. Go to original source... Go to PubMed...
    93. Liao CH, Yao TC, Chung HT, See LC, Kuo ML, Huang JL. Polymorphisms in the promoter region of RANTES and the regulatory region of monocyte chemoattractant protein-1 among Chinese children with systemic lupus erythematosus. J Rheumatol. 2004; 31:2062-7. Go to PubMed...
    94. Ye DQ, Yang SG, Li XP, Hu YS, Yin J, Zhang GQ et al. Polymorphisms in the promoter region of RANTES in Han Chinese and their relationship with systemic lupus erythematosus. Arch Dermatol Res. 2005; 297:108-13. Go to original source... Go to PubMed...
    95. Heydtmann M, Shields P, McCaughan G, Adams D. Cytokines and chemokines in the immune response to hepatitis C infection. Curr Opin Infect Dis. 2001; 14:279-87. Go to original source... Go to PubMed...
    96. Promrat K, Liang TJ. Chemokine systems and hepatitis C virus infection: is truth in the genes of the beholders? Hepatology. 2003; 38:1359-62. Go to original source... Go to PubMed...
    97. Fleury S, Li J, Simeoni E, Fiorini E, von Segesser LK, Kappenberger L et al. Gene transfer of RANTES and MCP-1 chemokine antagonists prolongs cardiac allograft survival. Gene Ther. 2006. Go to original source... Go to PubMed...
    98. Botella C, Marin L, Moya-Quiles R, Miras M, Sanchez-Bueno F, Minguela A et al. Lack of association between the -403G/A promoter polymorphism in the human CCL5/RANTES chemokine gene in liver transplant outcome. Transpl Int. 2006; 19:98-104. Go to original source... Go to PubMed...
    99. Wang CR, Guo HR, Liu MF. RANTES promoter polymorphism as a genetic risk factor for rheumatoid arthritis in the Chinese. Clin Exp Rheumatol. 2005; 23:379-84. Go to PubMed...
    100. Makki RF, al Sharif F, Gonzalez-Gay MA, Garcia-Porrua C, Ollier WE, Hajeer AH. RANTES gene polymorphism in polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis. Clin Exp Rheumatol. 2000; 18:391-3. Go to PubMed...
    101. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996; 382:722-5. Go to original source... Go to PubMed...
    102. Wang FS, Hong WG, Cao Y, Liu MX, Jin L, Hu LP et al. Population survey of CCR5 delta32, CCR5 m303, CCR2b 64I, and SDF1 3A allele frequencies in indigenous Chinese healthy individuals, and in HIV-1-infected and HIV-1-uninfected individuals in HIV-1 risk groups. J Acquir Immune Defic Syndr. 2003; 32:124-30. Go to original source... Go to PubMed...
    103. Lucotte G, Mercier G. Distribution of the CCR5 gene 32-bp deletion in Europe.J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 19:174-7. Go to original source... Go to PubMed...
    104. Mummidi S, Bamshad M, Ahuja SS, Gonzalez E, Feuillet PM, Begum K et al. Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus. J Biol Chem 2000; 275:18946-61. Go to original source... Go to PubMed...
    105. Shieh B, Liau YE, Hsieh PS, Yan YP, Wang ST, Li C. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol. 2000; 12:1311-8. Go to original source... Go to PubMed...
    106. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science. 1998; 282:1907-11. Go to original source... Go to PubMed...
    107. Ghilardi G, Biondi ML, Battaglioli L, Zambon A, Guagnellini E, Scorza R. Genetic risk factor characterizes abdominal aortic aneurysm from arterial occlusive disease in human beings: CCR5 Delta 32 deletion. J Vasc Surg. 2004; 40:995-1000. Go to original source... Go to PubMed...
    108. Petrkova J, Cermakova Z, Lukl J, Petrek M. CC chemokine receptor 5 (CCR5) deletion polymorphism does not protect Czech males against early myocardial infarction. J Intern Med. 2005; 257:564-6. Go to original source... Go to PubMed...
    109. Ortlepp JR, Schmitz F, Mevissen V, Weiss S, Huster J, Dronskowski R et al. The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J. 2004; 25:514-22. Go to original source... Go to PubMed...
    110. Kantor R, Bakhanashvili M, Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology. 2003; 61:238-40 Go to original source... Go to PubMed...
    111. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol. 2000; 102:98-106. Go to original source... Go to PubMed...
    112. Silversides JA, Heggarty SV, McDonnell GV, Hawkins SA, Graham CA. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler. 2004; 10:149-52. Go to original source... Go to PubMed...
    113. Kantarci OH, Morales Y, Ziemer PA, Hebrink DD, Mahad DJ, Atkinson EJ et al. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol. 2005; 169:137-43. Go to original source... Go to PubMed...
    114. Favorova OO, Andreewski TV, Boiko AN, Sudomoina MA, Alekseenkov AD, Kulakova OG et al. The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4- positive Russians. Neurology. 2002; 59:1652-5. Go to original source... Go to PubMed...
    115. Zapico I, Coto E, Rodriguez A, Alvarez C, Torre JC, Alvarez V. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun. 2000; 1:288-9. Go to original source... Go to PubMed...
    116. Pokorny V, McQueen F, Yeoman S, Merriman M, Merriman A, Harrison A et al. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann Rheum Dis. 2005; 64:487-90. Go to original source... Go to PubMed...
    117. Petrek M, Cermakova Z, Hutyrova B, Micekova D, Drabek J, Rovensky J et al. CC chemokine receptor 5 and interleukin-1 receptor antagonist gene polymorphisms in patients with primary Sjogrens syndrome. Clin Exp Rheumatol. 2002; 20:701-3. Go to PubMed...
    118. Spagnolo P, Renzoni EA, Wells AU, Copley SJ, Desai SR, Sato H et al. C-C chemokine receptor 5 gene variants in relation to lung disease in sarcoidosis. Am J Respir Crit Care Med. 2005; 172:721-8. Go to original source... Go to PubMed...
    119. Hall IP, Wheatley A, Christie G, McDougall C, Hubbard R, Helms PJ. Association of CCR5 delta32 with reduced risk of asthma. Lancet 1999; 354:1264-5. Go to original source... Go to PubMed...
    120. Mitchell TJ, Walley AJ, Pease JE, Venables PJ, Wiltshire S, Williams TJ et al. Delta 32 deletion of CCR5 gene and association with asthma or atopy. Lancet. 2000; 356:1491-2. Go to original source... Go to PubMed...
    121. Sandford AJ, Zhu S, Bai TR, Fitzgerald JM, Pare PD. The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. J Allergy Clin Immunol. 2001; 108:69- 73. Go to original source... Go to PubMed...
    122. Lusso P. HIV and the chemokine system: 10 years later. EMBO J. 2006; 25:447-56 Go to original source... Go to PubMed...
    123. OBrien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev. 2000; 177:99-111. Go to original source... Go to PubMed...
    124. An P, Martin MP, Nelson GW, Carrington M, Smith MW, Gong K et al. Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS. 2000; 14:2117-22. Go to original source... Go to PubMed...
    125. Ometto L, Bertorelle R, Mainardi M, Zanchetta M, Tognazzo S, Rampon O et al. Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children. J Infect Dis. 2001; 183:814-8. Go to original source... Go to PubMed...
    126. Winkler CA, Hendel H, Carrington M, Smith MW, Nelson GW, Obrien SJ et al. Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression. J Acquir Immune Defic Syndr. 2004; 37:1534-8. Go to original source... Go to PubMed...
    127. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murény PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet Lancet. 1998; 352:866-70. Go to original source... Go to PubMed...
    128. Clegg AO, Ashton LJ, Biti RA, Badhwar P, Williamson P, Kaldor JM et al. The Australian Long-Term Non-Progressor Study Group, CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term nonprogressors. AIDS 2000; 14:103. Go to original source... Go to PubMed...
    129. Singh KK, Barroga CF, Hughes MD, Chen J, Raskino C, McKinney RE et al. Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. J Infect Dis. 2003; 188:1461- 72. Go to original source... Go to PubMed...
    130. Li M, Song R, Masciotra S, Soriano V, Spira TJ, Lal RB et al. Association of CCR5 human haplogroup E with rapid HIV type 1 disease progression.AIDS Res Hum Retroviruses 2005; 21:111- 5. Go to original source... Go to PubMed...
    131. Kalev I, Oselin K, Parlist P, Zilmer M, Rajasalu T, Podar T et al. CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. J Diabetes Complications. 2003; 17:387-91. Go to original source... Go to PubMed...
    132. Mlynarski WM, Placha GP, Wolkow PP, Bochenski JP, Warram JH, Krolewski AS. Risk of diabetic nephropathy in type 1 diabetes is associated with functional polymorphisms in RANTES receptor gene (CCR5): a sex-specific effect. Diabetes. 2005; 54:3331-5. Go to original source... Go to PubMed...
    133. Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Piao L, Sakai K et al. Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes. Diabetes. 2002; 51:238-42. Go to original source... Go to PubMed...
    134. Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B et al. Frequency of the HIV-protective CC chemokine receptor 5 32/ 32 genotype is increased in hepatitis C. Gastroenterology 2002; 122:1721-28. Go to original source... Go to PubMed...
    135. Zhang M, Goedert JJ, Obrien TR. High frequency of CCR5- delta32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1. Gastroenterology 2003; 124:867-68 Go to original source... Go to PubMed...
    136. Chang HY, Ahn SH, Kim do Y, Shin JS, Kim YS, Hong SP et al. Association between CCR5 promoter polymorphisms and hepatitis B virus infection. Korean J Hepatol. 2005; 11:116-24.
    137. Fildes JE, Walker AH, Howlett R, Bittar MN, Hutchinson IV, Leonard CT et al. Donor CCR5 Delta32 polymorphism and outcome following cardiac transplantation. Transplant Proc. 2005; 37:2247-9. Go to original source... Go to PubMed...
    138. Hoffmann S, Park J, Jacobson LM, Muehrer RJ, Lorentzen D, Kleiner D et al. Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney Int. 2004; 66:1686-93. Go to original source... Go to PubMed...
    139. Moench C, Uhrig A, Lohse AW, Otto G. CC chemokine receptor 532 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl. 2004; 10:434-9. Go to original source... Go to PubMed...
    140. Aguilar F, Nunez-Roldan A, Torres B, Wichmann I, Sanchez- Roman J, Gonzalez-Escribano MF. Chemokine receptor CCR2/ CCR5 polymorphism in Spanish patients with systemic lupus erythematosus. J Rheumatol. 2003; 30:1770-4. Go to PubMed...
    141. Degerli N, Yilmaz E, Bardakci F. The delta32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin Biochem. 2005; 38:248-52. Go to original source... Go to PubMed...
    142. Dean M, Jacobson LP, McFarlane G, Margolick JB, Jenkins FJ, Howard OM et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res. 1999; 59:3561-4.
    143. Ortlepp JR, Vesper K, Mevissen V, Schmitz F, Janssens U, Franke A et al. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med. 2003; 81:363-7. Go to original source... Go to PubMed...
    144. Alonso-Villaverde C, Coll B, Parra S, Montero M, Calvo N, Tous M et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation. 2004; 110:2204-9. Go to original source... Go to PubMed...
    145. Yao TC, Wu KC, Chung HT, Shaw CK, Kuo ML, Wu CJ, Huang JL. MCP-1 gene regulatory region polymorphism in Chinese children with mild, moderate and near-fatal asthma. Allergy. 2004; 59:436-41. Go to original source... Go to PubMed...

    Return to the content